Takara Bio Inc. (JP:4974) has released an update.
Takara Bio Inc. showcased mixed financial performance in its 22nd term, with net sales dropping to 43,505 million yen from the previous year’s 78,142 million yen, and a significant decline in profit attributable to owners of the parent to 1,480 million yen, compared to 16,012 million yen in the 21st term. Despite these downturns, the company has maintained a robust shareholders’ equity ratio of 92% and continued to invest heavily in research and development, especially in its Reagents and Instruments business and CDMO services for regenerative medicine and gene/cell therapy, accounting for 19.1% of net sales.
For further insights into JP:4974 stock, check out TipRanks’ Stock Analysis page.
